InsiderTrades

Form 4 for MNPR Monopar Therapeutics

Accepted 2022-01-04 00:00:00 ET · period of report 2021-12-31 · accession 0001654954-22-000127 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2022-01-04 2021-12-31 MNPR Tsuchimoto Kim R CFO F - Tax $3.21 -501 4,189 -11% -$1,608
D 2022-01-04 2021-12-31 MNPR Tsuchimoto Kim R CFO M - OptEx — +1,221 4,690 +35% —
D 2022-01-04 2021-12-31 MNPR Tsuchimoto Kim R CFO M - OptEx $0.00 -1,221 14.7K -8% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2021-12-31 F D 501 $3.21 4,189 D — —
2 Common Common Stock 2021-12-31 M A 1,221 — 4,690 D — — (F1) Represents shares acquired on vesting and settlement of restricted stock units.
3 Derivative Restricted Stock Units 2021-12-31 M D 1,221 $0.00 14,652 D — · — to — 1,221 Common Stock (F1) Represents shares acquired on vesting and settlement of restricted stock units. (F2) On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.